ResMed (NYSE: RMD) reported Q3 EPS of $0.68, $0.01 worse than the analyst estimate of $0.69. Revenue for the quarter came in at $453.9 million versus the consensus estimate of $455.88 million.

For earnings history and earnings-related data on ResMed (RMD) click here.